--- title: Diagnostic Precision Blog | NIPT description: NIPT | A SeraCare blog focused on precision medicine and advanced clinical diagnostics --- [![SeraCare](https://blog.seracare.com/hs-fs/hubfs/0.%20Logos/SeraCare/SeraCare.png?width=400&name=SeraCare.png "SeraCare")](https://www.seracare.com) - [Home](https://blog.seracare.com/ngs) - [About](https://digital.seracare.com/about-blog) - [News and Events](http://www.seracare.com/NewsEvents/NewsCenter/tabid/354/Default.aspx) - [Contact](http://www.seracare.com/Contact/tabid/366/Default.aspx) ## [Diagnostic Precision](https://blog.seracare.com/) A SeraCare blog focused on precision medicine and advanced clinical diagnostics Choose your Article Focus | [NGS](https://blog.seracare.com/ngs) | [Molecular & Serology](https://blog.seracare.com/molecular-serology-blog) ## [Highlights from the ESHG and ESHRE 2020 Virtual Conferences](https://blog.seracare.com/ngs/nipt-and-pgt-at-the-virtual-conferences-2020) Category: [Reproductive Health](https://blog.seracare.com/ngs/tag/reproductive-health), [PGT](https://blog.seracare.com/ngs/tag/pgt), [Women's health](https://blog.seracare.com/ngs/tag/womens-health), [NIPT](https://blog.seracare.com/ngs/tag/nipt), [Non-invasive Prenatal Testing](https://blog.seracare.com/ngs/tag/non-invasive-prenatal-testing), [NGS](https://blog.seracare.com/ngs/tag/ngs), [Preimplantation genetic testing](https://blog.seracare.com/ngs/tag/preimplantation-genetic-testing) Posted by [Agnes Caruso,PhD](https://blog.seracare.com/ngs/author/agnes-carusophd) on Aug 20, 2020 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/Virtual%20conference.jpg)](https://blog.seracare.com/ngs/nipt-and-pgt-at-the-virtual-conferences-2020) The plans for this year’s NIPT and PGT conferences, like many others, were quickly derailed by the COVID-19 pandemic. The ESHG and ESHRE Annual Meetings were moved to virtual space and even though the format was a new experience, the science did not disappoint. Here we will share some of the highlights from the sessions. [Read More](https://blog.seracare.com/ngs/nipt-and-pgt-at-the-virtual-conferences-2020) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/nipt-and-pgt-at-the-virtual-conferences-2020#comments-listing) ## [Supporting High-Quality Testing for Women’s Health](https://blog.seracare.com/ngs/womens-health) Category: [Reproductive Health](https://blog.seracare.com/ngs/tag/reproductive-health), [HIV](https://blog.seracare.com/ngs/tag/hiv), [NIPT](https://blog.seracare.com/ngs/tag/nipt), [Non-invasive Prenatal Testing](https://blog.seracare.com/ngs/tag/non-invasive-prenatal-testing), [Breast Cancer](https://blog.seracare.com/ngs/tag/breast-cancer) Posted by [Agnes Caruso,PhD](https://blog.seracare.com/ngs/author/agnes-carusophd) on May 15, 2020 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/Women%20HCPS.jpg)](https://blog.seracare.com/ngs/womens-health) This week is National Women’s Health week1 and is dedicated to women to focus on their health and take steps to improve it. As Women’s Health week traditionally starts on Mother’s Day, we tend to focus primarily on Reproductive Health but it is important to look at the complete picture as some women encounter various conditions and treatments prior to starting a family. Women’s health encompasses things like fertility, pregnancy, infections, cancer, but also many underlying health conditions such as hypertension, diabetes, cardiovascular or respiratory conditions. Many of women’s health problems can be diagnosed by using advanced testing methods. As the technology develops and becomes more complex, ensuring the best performance of the tests is even more critical. With better testing, it is possible to improve outcomes for women around the world. [Read More](https://blog.seracare.com/ngs/womens-health) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/womens-health#comments-listing) ## [Do COVID-19 infections affect NIPT?](https://blog.seracare.com/ngs/do-covid-19-infections-affect-nipt) Category: [COVID-19](https://blog.seracare.com/ngs/tag/covid-19), [NIPT](https://blog.seracare.com/ngs/tag/nipt), [Non-invasive Prenatal Testing](https://blog.seracare.com/ngs/tag/non-invasive-prenatal-testing), [NGS](https://blog.seracare.com/ngs/tag/ngs), [SARS-CoV-2](https://blog.seracare.com/ngs/tag/sars-cov-2) Posted by [Prof. Joris Vermeesch, PhD](https://blog.seracare.com/ngs/author/prof-joris-vermeesch-phd) on Mar 26, 2020 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/pregnant_woman_and_doc-2.jpg)](https://blog.seracare.com/ngs/do-covid-19-infections-affect-nipt) We would like to present a guest blog from Prof. Joris Vermeesch, Ph.D. This blog originally posted on the Noninvasive Prenatal Testing Online Resource Page on the 17th March summarizes our current understanding of any possible interference of SARS-CoV-2 infection on the outcomes of NIPT testing. [Read More](https://blog.seracare.com/ngs/do-covid-19-infections-affect-nipt) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/do-covid-19-infections-affect-nipt#comments-listing) ## [Evolution of non-invasive prenatal testing (NIPT)](https://blog.seracare.com/ngs/evolution-of-non-invasive-prenatal-testing-nipt-testing) Category: [New Reference Material](https://blog.seracare.com/ngs/tag/new-reference-material), [trisomy](https://blog.seracare.com/ngs/tag/trisomy), [Reproductive Health](https://blog.seracare.com/ngs/tag/reproductive-health), [NIPT](https://blog.seracare.com/ngs/tag/nipt), [Non-invasive Prenatal Testing](https://blog.seracare.com/ngs/tag/non-invasive-prenatal-testing), [NGS](https://blog.seracare.com/ngs/tag/ngs), [#Quality](https://blog.seracare.com/ngs/tag/quality), [reference materials](https://blog.seracare.com/ngs/tag/reference-materials) Posted by [Agnes Caruso,PhD](https://blog.seracare.com/ngs/author/agnes-carusophd) on Feb 5, 2020 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/istock-48289588-medium.jpg)](https://blog.seracare.com/ngs/evolution-of-non-invasive-prenatal-testing-nipt-testing) Prenatal screening for aneuploidy has changed dramatically since the 1970s. Non-invasive methods developed in the 1980s and 1990s, combined measurements of maternal serum analytes and ultrasonography. The problem with those methods was not just a high false-negative rate of 12% to 23%, a high positive rate of 5% and a poor sensitivity, ranging from 50% to 95% 1. Uncertain results frequently led to invasive procedures such as amniocentesis or chorionic villi sampling to perform karyotyping on fetal samples. Both of those procedures carry a risk of miscarriage. [Read More](https://blog.seracare.com/ngs/evolution-of-non-invasive-prenatal-testing-nipt-testing) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/evolution-of-non-invasive-prenatal-testing-nipt-testing#comments-listing) ## [What is Non-Invasive Prenatal Testing (NIPT)?](https://blog.seracare.com/ngs/what-is-non-invasive-prenatal-testing-nipt) Category: [New Reference Material](https://blog.seracare.com/ngs/tag/new-reference-material), [trisomy](https://blog.seracare.com/ngs/tag/trisomy), [Reproductive Health](https://blog.seracare.com/ngs/tag/reproductive-health), [NIPT](https://blog.seracare.com/ngs/tag/nipt), [#Quality](https://blog.seracare.com/ngs/tag/quality), [reference materials](https://blog.seracare.com/ngs/tag/reference-materials) Posted by [SeraCare Team](https://blog.seracare.com/ngs/author/seracare-team) on Jan 20, 2020 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/Karyotype_cr-1.jpg)](https://blog.seracare.com/ngs/what-is-non-invasive-prenatal-testing-nipt) Fetal aneuploidy affects about 9 in 1,000 live births. The definition of aneuploidy is an abnormal number of chromosomes ; with 23 pairs of chromosomes in humans, 46 is the normal number, while aneuploidy individuals will have 45 or 47. In trisomy, there is one additional chromosome, typically chr21, 18 or 13 (it is not a coincidence that these are the smallest chromosomes in humans). Historically, the invasive methods amniocentesis and chorionic villus sampling (CVS) were used with risk to the pregnancy, with about a 1% chance of miscarriage due to the procedure. Non-invasive methods based upon ultrasound and serum biomarkers are useful screening tests, but were of limited reliability as they were indirect measures of chromosomal abnormalities1. Photograph courtesy of Flickr user Can H. [Read More](https://blog.seracare.com/ngs/what-is-non-invasive-prenatal-testing-nipt) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/what-is-non-invasive-prenatal-testing-nipt#comments-listing) ## [What lessons for liquid biopsy have been learned from fetal aneuploidy testing?](https://blog.seracare.com/ngs/what-lessons-for-liquid-biopsy-have-been-learned-from-fetal-aneuploidy-testing) Category: [liquid biopsy](https://blog.seracare.com/ngs/tag/liquid-biopsy), [NIPT](https://blog.seracare.com/ngs/tag/nipt), [ctDNA](https://blog.seracare.com/ngs/tag/ctdna) Posted by [Russell Garlick, PhD](https://blog.seracare.com/ngs/author/russell-garlick-phd) on Sep 30, 2016 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/Error_Report_Graph.png)](https://blog.seracare.com/ngs/what-lessons-for-liquid-biopsy-have-been-learned-from-fetal-aneuploidy-testing) Non-invasive prenatal screening (NIPS) is currently offered in over 80 countries, covering over 80 million annual births, with an estimated volume of over one million screening tests performed annually. First offered in 2011, there has been rapid adoption of these genomic tests in the marketplace. [Read More](https://blog.seracare.com/ngs/what-lessons-for-liquid-biopsy-have-been-learned-from-fetal-aneuploidy-testing) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/what-lessons-for-liquid-biopsy-have-been-learned-from-fetal-aneuploidy-testing#comments-listing) ## [The current state of non-invasive prenatal testing](https://blog.seracare.com/ngs/home/tabid/294/artmid/989/articleid/26/the-current-state-of-non-invasive-prenatal-testing.aspx) Category: [NIPT](https://blog.seracare.com/ngs/tag/nipt) Posted by [Yves Konigshofer, PhD](https://blog.seracare.com/ngs/author/yves-konigshofer-phd) on Dec 9, 2015 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/151208_baby_sm.jpg)](https://blog.seracare.com/ngs/home/tabid/294/artmid/989/articleid/26/the-current-state-of-non-invasive-prenatal-testing.aspx) Sometimes a single remark can effectively summarize a very complex problem. While the November 12, 2015 FDA Public Workshop on “Standard Based Approach to Analytical Performance Evaluation of Next Generation Sequencing In Vitro Diagnostic Tests” focused primarily on tests that look for germline and somatic variants, a comment made by Jared Maguire – Counsyl’s ‎Director of Computational Biology – about 1 hour 14 minutes into the workshop explained a lot about the current state of non-invasive prenatal testing (NIPT) and what patients, physicians and insurers are experiencing; more on that later. [Read More](https://blog.seracare.com/ngs/home/tabid/294/artmid/989/articleid/26/the-current-state-of-non-invasive-prenatal-testing.aspx) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/home/tabid/294/artmid/989/articleid/26/the-current-state-of-non-invasive-prenatal-testing.aspx#comments-listing) ## [Video Interview: Developing Aneuploidy Reference Materials](https://blog.seracare.com/ngs/home/tabid/294/artmid/989/articleid/24/video-interview-developing-aneuploidy-reference-materials.aspx) Category: [SeraSeq](https://blog.seracare.com/ngs/tag/seraseq), [clinical genomics](https://blog.seracare.com/ngs/tag/clinical-genomics), [NIPT](https://blog.seracare.com/ngs/tag/nipt), [reference materials](https://blog.seracare.com/ngs/tag/reference-materials) Posted by [Dale Yuzuki](https://blog.seracare.com/ngs/author/dale-yuzuki) on Nov 24, 2015 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/DRSeth-Video.jpg)](https://blog.seracare.com/ngs/home/tabid/294/artmid/989/articleid/24/video-interview-developing-aneuploidy-reference-materials.aspx) [Read More](https://blog.seracare.com/ngs/home/tabid/294/artmid/989/articleid/24/video-interview-developing-aneuploidy-reference-materials.aspx) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/home/tabid/294/artmid/989/articleid/24/video-interview-developing-aneuploidy-reference-materials.aspx#comments-listing) ## [What is Non-Invasive Prenatal Testing (NIPT)?](https://blog.seracare.com/ngs/home/tabid/294/artmid/989/articleid/23/what-is-non-invasive-prenatal-testing-nipt.aspx) Category: [NIPT](https://blog.seracare.com/ngs/tag/nipt) Posted by [Dale Yuzuki](https://blog.seracare.com/ngs/author/dale-yuzuki) on Nov 17, 2015 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/Karyotype_cr-1.jpg)](https://blog.seracare.com/ngs/home/tabid/294/artmid/989/articleid/23/what-is-non-invasive-prenatal-testing-nipt.aspx) Fetal aneuploidy affects about 9 in 1,000 live births. The definition of aneuploidy is an abnormal number of chromosomes ; with 23 pairs of chromosomes in humans, 46 is the normal number, while aneuploidy individuals will have 45 or 47. In trisomy, there is one additional chromosome, typically chr21, 18 or 13 (it is not a coincidence that these are the smallest chromosomes in humans). Historically, the invasive methods amniocentesis and chorionic villus sampling (CVS) were used with risk to the pregnancy, with about a 1% chance of miscarriage due to the procedure. Non-invasive methods based upon ultrasound and serum biomarkers are useful screening tests, but were of limited reliability as they were indirect measures of chromosomal abnormalities1.Photograph courtesy of Flickr user Can H. [Read More](https://blog.seracare.com/ngs/home/tabid/294/artmid/989/articleid/23/what-is-non-invasive-prenatal-testing-nipt.aspx) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/home/tabid/294/artmid/989/articleid/23/what-is-non-invasive-prenatal-testing-nipt.aspx#comments-listing) ## [Posters from AMP 2015 Available for Download](https://blog.seracare.com/ngs/home/tabid/294/artmid/989/articleid/21/posters-from-amp-2015-available-for-download.aspx) Category: [AMP](https://blog.seracare.com/ngs/tag/amp), [SeraSeq](https://blog.seracare.com/ngs/tag/seraseq), [NIPT](https://blog.seracare.com/ngs/tag/nipt), [Molecular Pathology](https://blog.seracare.com/ngs/tag/molecular-pathology), [cancer](https://blog.seracare.com/ngs/tag/cancer), [LDT](https://blog.seracare.com/ngs/tag/ldt), [Accuplex](https://blog.seracare.com/ngs/tag/accuplex) Posted by [Dale Yuzuki](https://blog.seracare.com/ngs/author/dale-yuzuki) on Nov 9, 2015 12:00:00 AM [![](https://blog.seracare.com/hubfs/Imported_Blog_Media/AMP_Posters.jpg)](https://blog.seracare.com/ngs/home/tabid/294/artmid/989/articleid/21/posters-from-amp-2015-available-for-download.aspx) The Association for Molecular Pathology (AMP) was founded 'to provide structure and leadership to the emerging field of molecular diagnostics', and publishes the Journal of Molecular Diagnostics. [Read More](https://blog.seracare.com/ngs/home/tabid/294/artmid/989/articleid/21/posters-from-amp-2015-available-for-download.aspx) 0 Comments [Click here to read/write comments](https://blog.seracare.com/ngs/home/tabid/294/artmid/989/articleid/21/posters-from-amp-2015-available-for-download.aspx#comments-listing) [All posts](https://blog.seracare.com/ngs/all) [Next](https://blog.seracare.com/ngs/tag/nipt/page/2) ### Subscribe Here!   ### Posts by Tag - [NGS (64)](https://blog.seracare.com/ngs/tag/ngs) - [reference materials (37)](https://blog.seracare.com/ngs/tag/reference-materials) - [clinical genomics (30)](https://blog.seracare.com/ngs/tag/clinical-genomics) - [ctDNA (29)](https://blog.seracare.com/ngs/tag/ctdna) - [cancer (24)](https://blog.seracare.com/ngs/tag/cancer) - [SeraSeq (16)](https://blog.seracare.com/ngs/tag/seraseq) - [cfDNA (14)](https://blog.seracare.com/ngs/tag/cfdna) - [NIPT (12)](https://blog.seracare.com/ngs/tag/nipt) - [RNA fusion (11)](https://blog.seracare.com/ngs/tag/rna-fusion) - [AACR (10)](https://blog.seracare.com/ngs/tag/aacr) - [AMP (10)](https://blog.seracare.com/ngs/tag/amp) - [liquid biopsy (10)](https://blog.seracare.com/ngs/tag/liquid-biopsy) - [FDA (7)](https://blog.seracare.com/ngs/tag/fda) - [ccfDNA (7)](https://blog.seracare.com/ngs/tag/ccfdna) - [LDT (6)](https://blog.seracare.com/ngs/tag/ldt) - [Assay Development (5)](https://blog.seracare.com/ngs/tag/assay-development) - [Reproductive Health (5)](https://blog.seracare.com/ngs/tag/reproductive-health) - [Accuplex (4)](https://blog.seracare.com/ngs/tag/accuplex) - [NTRK (4)](https://blog.seracare.com/ngs/tag/ntrk) - [Non-invasive Prenatal Testing (4)](https://blog.seracare.com/ngs/tag/non-invasive-prenatal-testing) - [QC Challenges (4)](https://blog.seracare.com/ngs/tag/qc-challenges) - [qc management (4)](https://blog.seracare.com/ngs/tag/qc-management) - [Lung Cancer (3)](https://blog.seracare.com/ngs/tag/lung-cancer) - [MRD (3)](https://blog.seracare.com/ngs/tag/mrd) - [New Reference Material (3)](https://blog.seracare.com/ngs/tag/new-reference-material) - [#Quality (2)](https://blog.seracare.com/ngs/tag/quality) - [EGFR (2)](https://blog.seracare.com/ngs/tag/egfr) - [Inherited Disease (2)](https://blog.seracare.com/ngs/tag/inherited-disease) - [Methylated DNA (2)](https://blog.seracare.com/ngs/tag/methylated-dna) - [Minimal Residual Disease (2)](https://blog.seracare.com/ngs/tag/minimal-residual-disease) - [Molecular Pathology (2)](https://blog.seracare.com/ngs/tag/molecular-pathology) - [PGT (2)](https://blog.seracare.com/ngs/tag/pgt) - [QC Management Software (2)](https://blog.seracare.com/ngs/tag/qc-management-software) - [TMB (2)](https://blog.seracare.com/ngs/tag/tmb) - [Women's health (2)](https://blog.seracare.com/ngs/tag/womens-health) - [myeloid cancer reference materials (2)](https://blog.seracare.com/ngs/tag/myeloid-cancer-reference-materials) - [ngs validation (2)](https://blog.seracare.com/ngs/tag/ngs-validation) - [trisomy (2)](https://blog.seracare.com/ngs/tag/trisomy) - [zika virus (2)](https://blog.seracare.com/ngs/tag/zika-virus) - [BioFidelity (1)](https://blog.seracare.com/ngs/tag/biofidelity) - [Breast Cancer (1)](https://blog.seracare.com/ngs/tag/breast-cancer) - [COVID-19 (1)](https://blog.seracare.com/ngs/tag/covid-19) - [Customer Testimonial (1)](https://blog.seracare.com/ngs/tag/customer-testimonial) - [Genomic Testing (1)](https://blog.seracare.com/ngs/tag/genomic-testing) - [HIV (1)](https://blog.seracare.com/ngs/tag/hiv) - [Immuno-Oncology (1)](https://blog.seracare.com/ngs/tag/immuno-oncology) - [PGS (1)](https://blog.seracare.com/ngs/tag/pgs) - [PGT-A (1)](https://blog.seracare.com/ngs/tag/pgt-a) - [Preimplantation genetic testing (1)](https://blog.seracare.com/ngs/tag/preimplantation-genetic-testing) - [QC Reporting (1)](https://blog.seracare.com/ngs/tag/qc-reporting) - [QC data management (1)](https://blog.seracare.com/ngs/tag/qc-data-management) - [Quality Management Systems (1)](https://blog.seracare.com/ngs/tag/quality-management-systems) - [SARS-CoV-2 (1)](https://blog.seracare.com/ngs/tag/sars-cov-2) - [bioinformatics (1)](https://blog.seracare.com/ngs/tag/bioinformatics) - [laboratory training (1)](https://blog.seracare.com/ngs/tag/laboratory-training) - [listeria (1)](https://blog.seracare.com/ngs/tag/listeria) - [methylated (1)](https://blog.seracare.com/ngs/tag/methylated) See all ### Recent Posts **About SeraCare** With over 30 years of experience as a leading partner to global in vitro diagnostics manufacturers and clinical testing laboratories, SeraCare’s clinical genomics technologies enable the promise of precision medicine by helping scientists and clinicians build and implement better clinical genomics assays. [Learn More](http://www.seracare.com/Company/WhoWeAre/tabid/335/Default.aspx)    - - - [Privacy Policy](http://www.seracare.com/PrivacyPolicy/tabid/211/Default.aspx)  |  [Legal Statement ](http://www.seracare.com/LegalStatement/tabid/212/Default.aspx) **Learn More** [Home](http://seracare.com/)  [About Us](http://seracare.com/Company/WhoWeAre/tabid/335/Default.aspx) [News and Events](http://www.seracare.com/NewsEvents/NewsCenter/tabid/354/Default.aspx)  [Blog](https://blog.seracare.com/)  [Contact](http://seracare.com/Contact/tabid/366/Default.aspx)  ![LGC+Marine-logo-FINAL-teal](https://blog.seracare.com/hs-fs/hubfs/1.%20Logos/LGC+Marine-logo-FINAL-teal.png?width=150&name=LGC+Marine-logo-FINAL-teal.png) 37 Birch Street Milford, MA 01757 [508-244-6400](tel:508-244-6400) l [800-676-1881](tel:800-676-1881) [info@seracare.com](mailto:info@seracare.com) ©2017 SeraCare Life Sciences, Inc. - [About SeraCare](http://www.seracare.com/Company/WhoWeAre/tabid/335/Default.aspx) - [Learn More](http://seracare.com/) - 37 Birch Street Milford, MA 01757 - Google Maps - 508-244-6400 - 508-634-3334 Fax - - - ![logo](https://blog.seracare.com/hubfs/logo.png "logo") 37 Birch Street Milford, MA 01757 508-244-6400 508-634-3334 Fax #### Products #### SeraCare #### Support & Resources - NGS & Digital PCR Tools - Controls & Reference Materials - Validation & Qualification Materials - Plasma & Serum Diluents & Derivatives - Cell Culture Reagents - KPL Antibodies & Conjugates - KPL Immunoassay Reagents & Kits - About Us - Careers - Press Releases - News Articles - Quality Systems - Terms & Conditions - Privacy Policy & Legal Statement - Register for an Account - Contact Us - Sign In - Resource Library - FAQs - Scientific Posters - White Papers - Videos